Chosa Oncology AB

Equities

CHOSA

SE0007784319

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-31 pm EST			5-day change	1st Jan Change
0.53 ^SEK	+51.43%		-.--%	-6.03%

Mar. 28	Chosa Oncology Names CFO, Chief Commercial Officer	MT
Mar. 28	CHOSA Oncology AB Announces Chief Financial Officer Changes	CI

CHOSA Oncology AB Publishes Results from Clinical Phase 2 Trial of Liposomal Formulation in Breast Cancer, Using Predictive Marker for Cisplatin

June 03, 2023 at 09:00 am EDT

CHOSA Oncology AB announced results from clinical phase 2 trial of liposomal formulation in breast cancer, using predictive marker for cisplatin. The company presents these important findings that have crystallized by deep clinical knowledge and years of dedication to developing LiPlaCis and its response prediction test DRP. Abstract number and title: 3130; Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.

Session: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology Poster Board: 328. Date and time: 3 June 2023; 8:00-11:00 CDT.

Latest news about Chosa Oncology AB

Chosa Oncology Names CFO, Chief Commercial Officer	Mar. 28	MT
CHOSA Oncology AB Announces Chief Financial Officer Changes	Mar. 28	CI
CHOSA Oncology Appoints Claus Frisenberg Pedersen as Chief Commercial Officer	Mar. 28	CI
Chosa Oncology AB Postpones Publication of Interim Report for the Second Quarter of 2023	23-08-27	CI
CHOSA Oncology AB Publishes Results from Clinical Phase 2 Trial of Liposomal Formulation in Breast Cancer, Using Predictive Marker for Cisplatin	23-06-03	CI
Chosa Oncology AB Announces Board Changes	23-05-26	CI
CHOSA Oncology AB Presents Clinical Phase 2 Results of LiPlaCis and its Drug Response Predictor Test at ASCO 2023	23-05-25	CI
RhoVac AB will Change its Name to CHOSA Oncology AB	23-02-15	CI
RhoVac AB has Changed its Name to CHOSA Oncology AB	23-02-10	CI
Rhovac AB Announces CEO Changes	23-01-18	CI
RhoVac AB Announces Board Changes	23-01-18	CI
Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction.	23-01-17	CI
Chosa ApS entered into an agreement to acquire RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction for SEK 30.4 million.	22-12-04	CI
RhoVac AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member	22-10-18	CI
RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022	22-08-26	CI
RhoVac AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Rhovac AB Announces Resignation of Anders Månsson as CEO	22-07-15	CI
RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint	22-05-29	CI
Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers	22-05-18	CI
RhoVac AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method	22-03-01	CI
RhoVac AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-11	CI
RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer	21-12-09	CI
RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers	21-11-29	CI

Chart Chosa Oncology AB

Duration

Period

More charts

Company Profile

Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHOSA ONCOLOGY AB	-6.03%	3.14M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.05%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.28%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs